Zomedica Accumulated Other Comprehensive Income from 2010 to 2024
| ZOM Stock | USD 0.13 0.00 0.00% |
Accumulated Other Comprehensive Income | First Reported 2013-12-31 | Previous Quarter -64 K | Current Value 300 K | Quarterly Volatility 682.3 K |
Check Zomedica Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Zomedica Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 183.8 K, Selling General Administrative of 30.5 M or Other Operating Expenses of 59.6 M, as well as many indicators such as Price To Sales Ratio of 7.4, Dividend Yield of 0.0 or PTB Ratio of 0.78. Zomedica financial statements analysis is a perfect complement when working with Zomedica Pharmaceuticals Valuation or Volatility modules.
Zomedica | Accumulated Other Comprehensive Income |
Latest Zomedica Pharmaceuticals' Accumulated Other Comprehensive Income Growth Pattern
Below is the plot of the Accumulated Other Comprehensive Income of Zomedica Pharmaceuticals Corp over the last few years. It is gains and losses not included in net income that are recorded in shareholders' equity, reflecting changes in the value of assets or liabilities that are not realized. Zomedica Pharmaceuticals' Accumulated Other Comprehensive Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Zomedica Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Accumulated Other Comprehensive Income | 10 Years Trend |
|
Accumulated Other Comprehensive Income |
| Timeline |
Zomedica Accumulated Other Comprehensive Income Regression Statistics
| Arithmetic Mean | 64,114 | |
| Geometric Mean | 0.00 | |
| Coefficient Of Variation | 739.49 | |
| Mean Deviation | 241,224 | |
| Median | 29,341 | |
| Standard Deviation | 474,118 | |
| Sample Variance | 224.8B | |
| Range | 2.3M | |
| R-Value | (0.16) | |
| Mean Square Error | 236.1B | |
| R-Squared | 0.02 | |
| Significance | 0.58 | |
| Slope | (16,597) | |
| Total Sum of Squares | 3.1T |
Zomedica Accumulated Other Comprehensive Income History
About Zomedica Pharmaceuticals Financial Statements
Zomedica Pharmaceuticals investors utilize fundamental indicators, such as Accumulated Other Comprehensive Income, to predict how Zomedica Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 48 K | 59.2 K |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Zomedica Pharmaceuticals Correlation against competitors. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.06) | Revenue Per Share 0.027 | Quarterly Revenue Growth 0.018 | Return On Assets (0.09) | Return On Equity (0.24) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.